BEM2, a RHO GTPase Activating Protein That Regulates Morphogenesis in S. cerevisiae, Is a Downstream Effector of Fungicidal Action of Fludioxonil

Fludioxonil belongs to the phenylpyrrole group of fungicides with a broad antifungal spectrum that has been widely used in agricultural practices for the past thirty years. Although fludioxonil is known to exert its fungicidal action through group III hybrid histidine kinases, the downstream effector of its cytotoxicity is poorly understood. In this study, we utilized a S. cerevisiae model to decipher the cytotoxic effect of fludioxonil. Through genome wide transposon mutagenesis, we have identified Bem2, a Rho GTPase activating protein, which is involved in this process. The deletion of BEM2 resulted in fludioxonil resistance. Our results showed that both the GAP and morphogenesis checkpoint activities of Bem2 were important for this. We also provided the genetic evidence that the role of Bem2 in the cell wall integrity (CWI) pathway and cell cycle regulation could contribute to the fludioxonil resistance phenotype.


Introduction
Fludioxonil belongs to the phenylpyrrole group of fungicides with a broad antifungal spectrum. It is used to control a variety of plant-pathogenic fungi [1][2][3][4]. Previous studies have revealed that fludioxonil acts as a fungicide through the inhibition of Nik1 orthologs or Group III hybrid histidine kinase (HHK3), which leads to the improper activation of the p38/HOG MAPK pathway in fungal pathogens [5][6][7][8][9]. Recent genetic studies on HHK3 orthologs have revealed that the null mutants are resistant to phenylpyrrole classes of fungicides [7,8], indicating that they could be the direct target of these fungicides or a signaling mediator for its fungicidal action that activates the p38/HOG MAPK pathway. The fungicidal action of fludioxonil causes the constitutive activation of p38/HOG MAPK pathways in fungi. This affects the cell in various ways, e.g., hyphal swelling and bursting at tips, metabolite leakage, alterations in cell wall synthesis, and defects in spore germination [10]. S. cerevisiae exhibits a natural resistance towards phenylpyrrole classes of fungicides. However, the heterologous expression of HHK3 orthologs from Magnaporthe grisea, Alternaria brassicicola, Candida albicans, Candida lusitaniae, or Debaryomyces hansenii confers a sensitivity towards these drugs to S. cerevisiae cells that indicates that the fungicidal effect of these compounds is mediated through HHK3 orthologs [7,[11][12][13][14]. Recent studies carried out with DRK1, a HHK3 ortholog from Blastomyces dermatitidis, indicate that fludioxonil does not bind to Drk1 [4]. However, it increases the intracellular level of methylglyoxal by inhibiting the enzyme triosephosphate isomerase. The accumulation of methylglyoxal causes covalent thiol modification of Drk1, which becomes cytotoxic to the cells resulting in the inappropriate activation of the p38/HOG MAPK pathway [4]. However, the details of the molecular events leading to the subsequent growth arrest or cell death remained unclear. A recent study has implicated cellular processes such as vesicular trafficking, endocytosis, vacuolar functions, and cytokinesis, in the cytotoxic effect of fludioxonil [14]. It is possible that fludioxonil could act through unknown cellular targets to regulate these cellular processes.
In this study, we, therefore, carried out a transposon-based approach to identify the signaling pathways or components controlling the fludioxonil sensitivity using S. cerevisiae model and found Bem2, a known Rho GAP (GTPase activating proteins), to be involved in the antifungal action of fludioxonil. The deletion of BEM2 resulted in fludioxonil resistance. We provide the genetic evidence that the role of Bem2 in the cell wall integrity (CWI) pathway and cell cycle regulation could contribute to the fludioxonil resistance phenotype.

Strains and Growth Conditions
Different deletion mutants used in this study were either procured from EUROSCARF or made in S. cerevisiae strains BY4742 or BY4741 background. YPD (1% yeast extract, 2% peptone, and 2% dextrose) and SD minimal medium (2% glucose and 0.67% yeast nitrogen base without amino acids) (Difco) with only required supplements were used for growing S. cerevisiae strains. Strains used in this study are listed in Supplementary Table S1. The transformation of S. cerevisiae strains with different plasmids was done by lithium acetate method [15]. Plasmids used in this study are listed in Supplementary Table S2.

Screening of S. cerevisiae Strain BY4742 with mTn3-LacZ/LEU2 Mutagenized Library
We obtained mTn3-LacZ/LEU2 mutagenized library [16] from the Yale Genome Analysis Center, New Haven, CT (http://ygac.med.yale.edu/mtn/reagent/avail_reagents/ lacZLEU2_lib_p.stm accessed on 20 August 2010). Plasmid DNA from the pools of the library was digested with NotI and the linear DNA corresponding to the 8 kb region was purified and transformed into S. cerevisiae strain BY4742 harbouring pClNik1 plasmid using lithium acetate protocol. Transformants were selected on SD-Leu medium. After 24 h of incubation, the plates were replica plated on SD media containing fludioxonil (50 µg/mL) and incubated further for 2-3 days at 30 • C. Colonies that appeared on these plates were designated as fludioxonil resistant mutants. To identify the dominant resistant mutant in this pool, each resistant mutant was crossed with S. cerevisiae strain BY4741/pClNik1. The resulting diploids that grew on SD media containing fludioxonil (50 µg/mL) were considered as dominant resistant mutant. To rule out whether the appearance of fludioxonil resistance was due to the transposon insertion in HOG1 or PBS2, osmo-sensitivity of all the resistant mutants was checked on plates containing 0.7 M NaCl. For transposon insertion in SSK1 gene each recessive fludioxonil-resistant mutant was crossed with ∆ssk1 (YPDahl143) harbouring pClNik1 and fludioxonil sensitivity of the resulting diploids was checked on SD media containing fludioxonil (50 µg/mL). Transposon mutants corresponding to those diploids still resistant to fludioxonil were discarded. To identify the transposon insertion site, genomic DNA immediately adjacent to the inserted lacZ sequences was obtained by a plasmid rescue method using pRSQ-URA3 plasmid (GenBank U64694). Positive plasmids were sequenced using primer LacZ R having the binding site within the lacZ sequences of the terminal repeats. The nucleotide sequences were compared with the GenBank database using the BLASTN program.

Construction of BEM2 Mutants
The coding sequence of BEM2 along with the upstream promoter region (7.1 kb) was amplified in two parts using BY4742 genomic DNA as a template. The first PCR fragment (~4.3 kb) was amplified by primers Bem2 PF and Bem2 Kas R, and the second fragment (~2.8 kb) was amplified by primers Bem2 Kas F and Bem2 ORF R ( Table 1). The second PCR fragment (~2.8 kb) was cloned in the plasmid vector pGEM7z (Promega, Madison, WI, USA) digested by Sac1 restriction enzyme and treated with Klenow for blunt-end ligation. Positive clone with the desired orientation of the insert was selected by restriction enzyme digestion and was further used to clone the first fragment of (~4.3 kb) at Xho1/Kas1 sites. The resultant plasmid pGEM7z-BEM2 was confirmed by restriction digestion and DNA sequencing. Full-length BEM2 ORF along with its promoter was then excised and subcloned in pRS313 [17] vector at Xho1/Sac1 sites to obtain pBEM2-313. The transformants were screened for the presence of insert by restriction digestion and confirmed by DNA sequencing. R2003A mutant was generated by replacing arginine with alanine residue at 2003 position in the GAP domain by site-directed mutagenesis using overlap extension PCR. First PCR was done to amplify~1.4 kb fragment using Bem2 Sph1 F and R2003A R primers. Second PCR was done to amplify~504 bp fragment using R2003A F and Bem2 ORF R primers. These PCR products were used as the template for the final overlap extension PCR to amplify~1.8 kb fragment using Bem2 Sph1 F and Bem2 ORF R primers.~1.8 kb PCR fragment was digested with Sph1 and Sac1 restriction enzymes and then cloned in pBEM2-313 at Sph1/Sac1 sites replacing the original fragment to obtain pBEM2-GAP. Similarly, ∆2-1749 mutant was made by overlap extension PCR using primer pairs, Bem2 PF/∆2-1749R primers and ∆2-1749 F/Bem2 ORF R. The resultant plasmid pBEM2-1749 was confirmed by restriction digestion and automated DNA sequencing. To construct double deletion mutants, BEM2 was disrupted in S. cerevisiae ∆fks2, ∆bni1, ∆bnr1, ∆skn7, ∆crz1, ∆mbp1, ∆swi6, and ∆swe1 procured from EUROSCARF. The disruption cassette with URA3 (1.7 kb) or LEU2 marker (2.5 kb) genes was amplified from plasmid pUG72 or pUG73 [18], respectively, using primers Bem2 dis F and Bem2 dis R. PCR fragment (2 µg) was then transformed into individual deletion mutant. Correct integration was confirmed by diagnostic PCR and DNA sequencing of PCR fragments.

Construction of MPK1 Mutants
We amplified full-length MPK1 ORF (1.4 kb) along with its native promoter (555 bp) and terminator region (130 bp) using MPK1 F and MPK1 R as forward and reverse primers from S. cerevisiae genomic DNA. PCR product and vector pRS313 digested with BamH1 and Xho1 were ligated and transformed in E. coli strain DH10B2. Transformants were screened by restriction digestion and positive clone pMPK1-313 was confirmed by automated DNA sequencing.
Three mutants of Mpk1, ATP binding site mutant (K54R), substrate binding (SB) site mutant (R196A) and D-motif binding (DB) site mutant (K83A) were made by site-directed mutagenesis using overlap extension PCR. First PCR was done to amplify 717 bp for K54R, 1.1 kb for R196A, 805 bp for K83A using MPK1 F/K54R R, MPK1 F/R196A R, and MPK1 F/K83A R primer sets, respectively. Second PCR was done to amplify 1.4 kb for K54R, 997 bp for R196A, 1.3 kb for K83A using K54R F/MPK1 R, R196A F/MPK1 R, and K83A F/MPK1 R primer sets, respectively. All the fragments were gel purified and used as the template for final overlap extension PCR to amplify 2.1 kb PCR fragments of all mutants using forward MPK1 F and reverse MPK1 R primers. All mutant constructs were then cloned in pRS313 at BamH1 and Xho1 site as described above to get pMPK1-83, pMPK1-54, and pMPK1-196. Positive clones were confirmed by automated DNA sequencing.

Relative Growth Assay of mpk1 Mutants
pMPK1-313 (MPK1) and its mutant constructs (pMPK1-83, pMPK1-54, and pMPK1-196) were transformed in Y00993 (∆mpk1) strain along with p426ClNik1. The growth pattern of these strains was checked on SD plate (-His-Ura) containing 25 µg/mL fludioxonil. For liquid media growth assay, Y00993 (∆mpk1) strain expressing MPK1, and its mutant constructs were grown overnight in SD media (-His-Ura) and then re-inoculated in the fresh media at an initial OD 600 of 0.1. Cells were grown for four hours at 28 • C with shaking to attain log phase. The cultures were then inoculated in the 96 well plates (98 µL/well). All wells were then dispensed with serial dilutions of fludioxonil (2 µL/well). The final concentration of fludioxonil in the well was from 0-24 µg/mL. OD 600 of the culture was measured at 0 h and after 24 h of incubation at 28 • C.

Western Blotting
The dually phosphorylated Hog1 in the S. cerevisiae strain was detected by western blotting as previously described [19]. Cells were treated with 25 µg/mL fludioxonil for various time periods ranging from 5 min to 3 h. The total cell extract (approx. 20 µg of protein) from each sample was blotted onto the nitrocellulose membrane. The dually phosphorylated Hog1 was detected using an anti-dually phosphorylated p38 antibody (Cell Signaling Technology, Danvers, MA, USA). The level of Hog1 was seen in the same blot after re-probing with anti-Hog1 antibody (Y-215, Santa Cruz Biotechnology, Dallas, TX, USA). For detecting phosphorylated Mpk1, anti-phospho-p44/42 MAPK (Thr202/Tyr204) (Rabbit) antibody was used (Cell Signaling Technology, Danvers, MA, USA).

Identification of Fludioxonil Resistant bem2 Mutant Strain through mTn3-LacZ/LEU2 Mutagenized Library
We have utilized a S. cerevisiae model to conduct the genome-wide screening for fludioxonilresistant mutants using mTn3-LacZ/LEU2 mutagenized library. We have expressed ClNik1, an HHK3 ortholog from the yeast C. lusitaniae, in the S. cerevisiae strain that conferred fludioxonil sensitivity to the host [20]. Previously, we have utilized this model to understand the antifungal activity of fludioxonil [14]. In this study, S. cerevisiae strain BY4742 harbouring plasmid pClNik1 [20] was transformed with mTn3-LacZ/LEU2 mutagenized library to isolate fludioxonil-resistant mutants that grew on SD-agar plate containing 50 µg/mL of fludioxonil. Out of approximately 27,000 transformants, 40 fludioxonil resistant mutants were obtained. After discarding the dominant resistant strains and the strains bearing mutations in genes of the p38/HOG MAPK pathway by genetic analysis, twelve recessive resistant strains were shortlisted for further analysis. Among these strains, the site of mTn3 insertions could be identified unambiguously only in seven resistant strains, out of which two strains had an insertion in the BEM2 gene, and the rest showed disruption in the coding region of the following genes: ENV11, BNI4, SIR1, ATG1, and DCG1. To confirm that the resistance phenotype was indeed due to the deletion in the identified genes, we transformed pClNik1 into ∆bem2, ∆env11, ∆bni4, ∆sir1, ∆atg1, and ∆dcg1 strains obtained from EUROSCARF and checked their fludioxonil resistance ( Figure 1A). We observed that only the strain carrying a deletion in BEM2 showed resistance to fludioxonil ( Figure 1A). The strain ∆env11 showed only a partial resistance phenotype, while the other strains were sensitive to fludioxonil as was the wild type strain. Therefore, the fludioxonil resistance phenotype exhibited by bni4, sir1, atg1, and dcg1 mutants obtained by transposon mutagenesis earlier could be due to the secondary site mutation unlinked to the transposon insertion site. Alternatively, the truncated protein due to transposon insertion could be responsible for the fludioxonil resistance phenotype (Supplementary Table S3). It is established that fludioxonil treatment causes the phosphorylation of Hog1 in the S. cerevisiae strain expressing ClNik1 [14]. Interestingly, we also observed the phosphorylation of Hog1 within 15 min of the exposure to the drug in the ∆bem2/pClNik1 strain, and it was maintained even after a 3 h of treatment ( Figure 1B). This result suggests that fludioxonil resistance exhibited by the ∆bem2 strain was not through the inactivation of the p38/HOG MAPK pathway and Bem2 might act downstream of Hog1 in fludioxonil toxicity. Bem2 is a Rho GTPase activating protein (Rho-GAP) that acts as GAP for various GTPases Rho1, Rho2, Rho4, and Cdc42 [21][22][23][24][25][26]. Since the deletion of BEM2 leads to fludioxonil resistance, we also checked the fludioxonil sensitivity of the deletion strains of other Rho GAPs, e.g., Y02390 (∆bag7), Y04225 (∆sac7), and Y03937 (∆lrg1). The expression of ClNik1 in these mutant strains conferred sensitivity to fludioxonil that was similar to that of the wild type strain (Figure 2A). In S. cerevisiae, Rga1, Rga2, and Bem3 are known to act as GAP for Cdc42 along with Bem2. Therefore, we also checked the fludioxonil sensitivity of the strains carrying deletion in these GAPs by dilution spotting. The strains ∆rga1, ∆rga2, and ∆bem3 expressing ClNik1 failed to grow on the fludioxonil plate ( Figure 2B). Thus, our results indicate that the fludioxonil resistance phenotype is exclusive to the Bem2.

The Role of BEM2 in the Antifungal Activity of Fludioxonil
To determine whether the GAP activity or the morphogenesis checkpoint activity of Bem2 is required for fludioxonil sensitivity, we created two functional mutants of BEM2, R2003A and ∆2-1749. The R2003A mutant has a point mutation in the GAP domain, which completely abolishes the GAP activity of Bem2. In contrast, the ∆2-1749 mutant has a deletion in the N terminal region of Bem2, which is essential for its role in the morphogenesis checkpoint [25]. As expected, the expression of full-length BEM2 in the ∆bem2/p426ClNik1 strain completely reversed its resistant phenotype. However, R2003A and ∆2-1749 mutants also remained resistant to fludioxonil ( Figure 3A). These results suggest that the functional GAP domain and N terminal region of Bem2 are crucial for their role in fludioxonil toxicity. Recently it has been suggested that methylglyoxal treatment phenocopies fludioxonil treatment in S. cerevisiae [4]. Fludioxonil treatment triggered the accumulation of cytosolic methylglyoxal in fungi, which modifies the activity of HHK3 and causes cytotoxicity. Therefore, we checked whether the deletion of BEM2 could affect the sensitivity of the yeast towards methylglyoxal. For this, BY4741 and ∆bem2 strains carrying plasmid pClNik1 were grown in SD media or SD media supplemented with two different concentrations of methylglyoxal for 24 h. Relative growth of the strain at each concentration of methylglyoxal was expressed as a percentage of the growth (OD 600 ) observed in the absence of methylglyoxal. At a lower concentration (5 mM) of methylglyoxal the relative growth of ∆bem2 and parental BY4741 was quite similar. However, at a higher concentration of methylglyoxal (25 mM), ∆bem2 showed significantly better growth than the parental strain BY4741 ( Figure 3B). Thus, the deletion of BEM2 also conferred methylglyoxal tolerance in S. cerevisiae. Bem2 is a negative regulator of small GTPase Rho1, which acts as a master regulator of various cellular processes, including the CWI pathway, actin organization, and polarized secretion [27]. At the site of polarized growth, Rho1 activates various downstream effector proteins such as Fks1/Fks2, Bni1, Bnr1, Swi4, Swi6, Crz1, and Skn7. Furthermore, fludioxonil treatment also affects the cell cycle dynamics and impairs cytokinesis [14]. Therefore, we hypothesized that if Bem2 acts upstream of these effector proteins by regulating Rho1 activity and its morphogenesis checkpoint role, then the deletion of the downstream effector proteins in the BEM2 deletion background will affect its sensitivity towards fludioxonil. We shortlisted a set of genes involved in BEM2 controlled cellular processes and checked the fludioxonil sensitivity of all the double deletion strains expressing ClNik1. We observed that the deletion of SWE1 and SWI6 suppressed the resistance of ∆bem2 completely (Figure 3C), while the deletion of BEM2 in mpk1 and swi4 background could not be made as they appear to be lethal to the cells. Synthetic lethality between bem2 and swi4 mutants has been reported previously [28]. Interestingly, the deletion of SKN7 suppressed the resistance partially. In contrast, the deletion of BNI1, BNR1, CRZ1, FKS2, and MBP1 in the BEM2 deletion background did not affect the drug resistance phenotype ( Figure 3C). These results indicate that the genes involved in the CWI pathway and cell cycle regulation contribute to the viability of ∆bem2 cells in response to fludioxonil.

The Activation of CWI Pathway upon Fludioxonil Treatment
Bem2 modulates the activity of Rho1, which is a master regulator CWI pathway in yeast. Previous studies showed that the CWI pathway plays a very important role in the antifungal action of fludioxonil [29,30]. The ∆mpk1 MAPK mutant strain of C. neoformans exhibited fludioxonil hypersensitivity. Moreover, in Aspergillus fumigatus, cell wall composition was affected by fludioxonil treatment [30]. To further explore the role of the CWI pathway, we checked the levels of dually phosphorylated Mpk1 using immunoblotting ( Figure 4A). Fludioxonil treatment caused Mpk1 phosphorylation within 15 min and was maintained up to 3 h in both BY4742 and ∆bem2 strains. Interestingly, the basal level of phosphorylated Mpk1 was seen even in the absence of the drug in the ∆bem2 strain, confirming the over activation of Mpk1 in this genetic background. Thus, fludioxonil activates the CWI pathway in the S. cerevisiae strain expressing ClNik1.
Mpk1 phosphorylation regulates the expression of various genes through further activation of two distinct transcription factors, SBF (Swi4/Swi6) and Rlm1 [31][32][33][34]. Mpk1 binds to its substrates and regulators through two distant interacting sites, the D motif binding site (DB) and substrate binding site (SB). Mpk1 binding to Swi4 requires its intact DB site but not the SB site; however, the SB site seems crucial for Rlm1-driven transcription [35]. We generated three mutants of Mpk1, ATP binding site mutant (K54R), substrate binding (SB) site mutant (R196A), and D-motif binding (DB) site mutant (K83A), by site-directed mutagenesis. The growth pattern of the mutant strains expressing ClNik1 was checked on fludioxonil agar media. We observed that the full-length MPK1 and DB site mutant K83A alleviated the hypersensitivity of the ∆mpk1 strain towards fludioxonil. On the other hand, the ATP binding site mutant K54R behaved as a non-functional kinase and showed hypersensitivity to the drug. Interestingly, the SB site mutant R196A showed lesser growth than full-length MPK1 ( Figure 4B). To better understand the growth pattern, we also checked the growth of these strains in the presence of serial concentrations of fludioxonil (0-24 µg/mL) in liquid media. We observed the same pattern, as R196A mutant showed a significant two-fold decrease in growth compared to MPK1 at 0.75 µg/mL fludioxonil, which indicated that Rlm1 binding to the SB site was crucial for Mpk1 function in fludioxonil mechanism of action ( Figure 4C). Thus, our results confirm that cell wall integrity plays a central role in the fludioxonil tolerance.

Discussion
Fludioxonil toxicity is not solely the outcome of increased osmotic pressure, but other cellular processes, i.e., cytokinesis, cell trafficking, and cell wall integrity, are compromised, which contributes to the growth arrest and cell death [14,30]. This study takes a step further to identify genes or pathways involved in the fludioxonil mode of action. We performed insertion mutagenesis to screen for the strains resistant to fludioxonil. Our screening identified BEM2 as a potential regulator of fludioxonil toxicity. Bem2 encodes a Rho GTPase activating protein that regulates GTPases to maintain morphogenesis and cell polarity in S. cerevisiae [25]. BEM2 deletion leads to various cellular defects, which includes an actin polarity defect, a septin assembly defect, a cytokinesis defect, hyper-activation of CWI pathway, enlarged vacuoles, and a morphogenesis checkpoint defect [23,25,[36][37][38][39][40]. Bem2 acts as GAP proteins for Rho1 and Cdc42 [27]. Apart from Bem2, Sac1, Lrg1, and Bag7 also function as GAP for Rho1 protein in S. cerevisiae. Similarly, Cdc42 is also regulated by other GAP proteins, e.g., Rga1, Rga2, and Bem3. Our results showed that the fludioxonil sensitivity of the cell was not affected by the deletion of anyone of these GAPs (Figure 2). Thus, Bem2 is the only Rho GAP that seems to have a role in fludioxonil toxicity.
Moreover, the dually phosphorylated Hog1 was detected within fifteen minutes of fludioxonil treatment in the ∆bem2/pClNik1 strain ( Figure 1B), which ruled out the possibility that fludioxonil resistance exhibited by the ∆bem2 strain was due to the inactivation of the p38/HOG MAPK pathway. This observation suggests that Bem2 is either acting downstream of Hog1 or the fludioxonil resistance of ∆bem2 strain is entirely an independent phenomenon. To delineate the role of Bem2 in fludioxonil sensitivity, we constructed two functional mutants, R2003A and ∆2-1749, which abolish the GAP activity and morphogenesis checkpoint role, respectively. The expression of full-length BEM2 restored the fludioxonil sensitivity to the ∆bem2/pClNik1 strain. However, both the mutant constructs were still resistant to fludioxonil, indicating the role of both the GAP domain and the N terminal region of Bem2 in conferring fludioxonil sensitivity.
Furthermore, we performed a genetic interaction study to determine how the downstream effector of Bem2 contributed to the drug resistance phenotype. Our results confirmed that Swi6, Swe1, and Skn7 play a crucial role in the resistance phenotype of the ∆bem2/pClNik1 strain. Since swi4 exhibit synthetic lethal interactions with bem2, its effect on the fludioxonil resistance phenotype could not be tested directly. Swi6 and Swi4 directly contribute to CWI transcriptional program whereas Swe1 is required for the morphogenesis checkpoint [41]. This checkpoint delays the cell cycle at the G2 phase in response to stresses that perturb the actin cytoskeleton and septin or bud formation. Our results indicate that the morphogenesis checkpoint role of BEM2 is also crucial for drug-mediated activity ( Figure 3A). Interestingly, the CWI pathway also plays an important role in the morphogenesis checkpoint. Skn7 is regulated by both the p38/HOG MAPK pathway and Rho1GTPase and has a role in cell wall synthesis [10,27]. The role of SKN7 in the fungicidal action of fludioxonil has also been presented recently [11,30]. Our results indicate that the deletion of SKN7 in the bem2 strain might reduce cell wall rigidity; hence, cells become more sensitive to the drug.
The hypersensitivity of mpk1 mutants and the overrepresentation of cell wall genes in the deletion sensitivity profiling (DSP) assay of fludioxonil indicate that the CWI pathway contributes to the resistance to the drug [14]. The CWI pathway regulates the new cell wall synthesis, which is pivotal for budding and polarized growth in fungi. An early study in C. neoformans revealed that the deletion of MPK1 leads to fludioxonil hypersensitivity [29], and similar results were observed in the S. cerevisiae strain expressing ClNik1 [14,42]. We have observed Mpk1 phosphorylation within 15 min of fludioxonil treatment in both BY4742 and ∆bem2 strains ( Figure 4A). Bem2 is a negative regulator of the CWI pathway, and its deletion leads to constitutive Mpk1 activation [43,44]. The basal level of phosphorylated Mpk1 was observed even under normal conditions in the BEM2 deletion strain. The role of Mpk1 in fludioxonil sensitivity was further explored by creating a set of mutations: K83A, R196A, and K54R, which abolished the binding of proteins at the DB site, the SB site, and ATP binding, respectively. The SB site mutant R196A, which was defective in transcription through Rlm1, showed the two-fold decrease in growth compared to MPK1, suggesting the role of Rlm1-driven transcription of cell wall genes in providing resistance to the cell on fludioxonil treatment ( Figure 4C). All these observations indicated the role of cell wall integrity and morphogenesis checkpoint control in maintaining cell viability during fludioxonil treatment. Various environmental and integral cellular factors also trigger the activation of the CWI pathway thatfurther regulates cell cycle, morphogenesis checkpoint, and septum dynamics [45], and Bem2 also has a role in these processes. Summing up, our work provides a novel chemical genetic link between Bem2 and the cell wall integrity pathway. We speculate that in the presence of fludioxonil, Bem2 negatively regulates the cell wall integrity pathway kinase Mpk1, and the transcription factor Skn7 through Rho1 GTPase, as depicted schematically in Figure 4D. In future, deciphering this at the molecular level would provide a novel insight into the fungicidal action of fludioxonil.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10 .3390/jof8070754/s1, Table S1: List of strains used in this study; Table S2: List of plasmids used in this study [46,47]; Table S3: Details of transposon insertion sites. Data Availability Statement: All data generated or analyzed during this study are included within the article.